Dr. Ann Burchell is Research Director at the Department of Family and Community Medicine and Scientist at the MAP Centre for Urban Health Solutions at St. Michael’s Hospital, Toronto. She is a Canada Research Chair in Sexually Transmitted Infection Prevention. She holds degrees in epidemiology from the University of Toronto (MSc) and McGill University (PhD) and has academic appointments as Associate Professor, Department of Family and Community Medicine, Faculty of Medicine, and Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto; Adjunct Professor, Division of Cancer Epidemiology, McGill University; and Adjunct Scientist, Institute for Clinical Evaluative Medicine, Toronto.

Dr. Burchell’s research program focuses on the epidemiology of human immunodeficiency virus (HIV) infection, human papillomavirus (HPV), syphilis, and other sexually transmitted infections (STIs). Its goal is to generate evidence for effective and practical strategies to prevent STIs and STI-related cancers in high-risk populations, including people living with or at risk for HIV.

She has extensive methodological experience in the design and implementation of: observational longitudinal studies with primary and secondary data; sexual behaviour and health-access questionnaires; natural history studies using laboratory markers of infection; and pragmatic randomized trials for HPV prevention and improved screening for syphilis, cervical and anal cancer. She currently holds a Foundation Grant from the Canadian Institutes of Health Research.

Visit the Estimate Lab website.

Recent Publications

  1. Laurie, C, El-Zein, M, Tota, JE, Tellier, PP, Coutlée, F, Burchell, AN et al.. Impact of a carrageenan gel on viral load of genital human papillomavirus infections in sexually active women: Findings from the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) trial. J Med Virol. 2024;96 (4):e29604. doi: 10.1002/jmv.29604. PubMed PMID:38606779 .
  2. Morais, S, Wissing, MD, Khosrow-Khavar, F, Burchell, AN, Tellier, PP, Coutlée, F et al.. Serologic response to human papillomavirus genotypes following vaccination: findings from the HITCH cohort study. Infect Dis (Lond). 2024;56 (1):66-72. doi: 10.1080/23744235.2023.2277390. PubMed PMID:37994805 .
  3. Arthur, AW, El-Zein, M, Burchell, AN, Tellier, PP, Coutlée, F, Franco, EL et al.. Epidemiology of genital human papillomavirus infections in sequential male sex partners of young females. Clin Microbiol Infect. 2024;30 (2):247-253. doi: 10.1016/j.cmi.2023.11.009. PubMed PMID:37981060 .
  4. Puyat, JH, Wilton, J, Fowokan, A, Janjua, NZ, Wong, J, Grennan, T et al.. COVID-19 vaccine effectiveness by HIV status and history of injection drug use: a test-negative analysis. J Int AIDS Soc. 2023;26 (10):e26178. doi: 10.1002/jia2.26178. PubMed PMID:37885156 PubMed Central PMC10603274.
  5. Hammond, K, Lee, T, Vulesevic, B, Singer, J, Needham, J, Burchell, AN et al.. Preventative behaviours and COVID-19 infection in a Canadian cohort of people living with HIV. AIDS Res Ther. 2023;20 (1):73. doi: 10.1186/s12981-023-00571-7. PubMed PMID:37858245 PubMed Central PMC10588118.
  6. Arthur, AW, El-Zein, M, Burchell, AN, Tellier, PP, Coutlée, F, Franco, EL et al.. Detection and Clearance of Type-Specific and Phylogenetically Related Genital Human Papillomavirus Infections in Young Women in New Heterosexual Relationships. J Infect Dis. 2024;229 (3):691-706. doi: 10.1093/infdis/jiad450. PubMed PMID:37824429 PubMed Central PMC10938200.
  7. Nicolau, IA, Moineddin, R, Antoniou, T, Brooks, JD, Gillis, JL, Kendall, CE et al.. Trends in infection-related and infection-unrelated cancer incidence among people with and without HIV infection in Ontario, Canada, 1996-2020: a population-based matched cohort study using health administrative data. CMAJ Open. 2023;11 (5):E894-E905. doi: 10.9778/cmajo.20220230. PubMed PMID:37816545 PubMed Central PMC10569814.
  8. Perri, M, Hapsari, AP, Craig-Neil, A, Ho, J, Cattaneo, J, Gaspar, M et al.. An evaluation of an employment assistance program focused on people living with HIV in Toronto, Canada. AIDS Care. 2024;36 (4):500-507. doi: 10.1080/09540121.2023.2253505. PubMed PMID:37756653 .
  9. Costiniuk, CT, Singer, J, Lee, T, Galipeau, Y, McCluskie, PS, Arnold, C et al.. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada. AIDS. 2023;37 (12):F25-F35. doi: 10.1097/QAD.0000000000003680. PubMed PMID:37534695 PubMed Central PMC10481923.
  10. Puyat, JH, Fowokan, A, Wilton, J, Janjua, NZ, Wong, J, Grennan, T et al.. Risk of COVID-19 hospitalization in people living with HIV and HIV-negative individuals and the role of COVID-19 vaccination: A retrospective cohort study. Int J Infect Dis. 2023;135 :49-56. doi: 10.1016/j.ijid.2023.06.026. PubMed PMID:37419410 .
Search PubMed

Affiliations & Other Activities

  • Associate Professor, Dalla Lana School of Public Health, University of Toronto,
  • Associate Professor, Department of Family and Community Medicine, University of Toronto